The Desmoteplase in Acute Ischemic Stroke Trial (DIAS)

Werner Hacke, Gregory W. Albers, Yasir Al‐Rawi, Julien Bogousslavsky, Antonio Dávalos, Michael Eliasziw, Michael Fischer, Anthony J. Furlan, Markku Kaste, Kennedy R. Lees,

Stroke · 2004 · 1K citations · 11 references

DOIFull text

Open access

Abstract

Intravenous desmoteplase administered 3 to 9 hours after acute ischemic stroke in patients selected with perfusion/diffusion mismatch is associated with a higher rate of reperfusion and better clinical outcome compared with placebo. The sICH rate with desmoteplase was low, using doses up to 125 microg/kg.

References

11